Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases

Women's Health

Volumn 6, Issue 3, 2010, Pages 431-442

  Elliott, Amy B ^a   Chakravarty, Eliza F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune disease; Disease modifying antirheumatic drugs; Immunosuppressive medications; Lactation; Medication; Pregnancy; Teratogenicity; Therapy; TNF inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BETAMETHASONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DICLOFENAC; DOXORUBICIN; ETANERCEPT; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INFLIXIMAB; KETOROLAC; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TOLMETIN; TUMOR NECROSIS FACTOR INHIBITOR;

AUTOIMMUNE DISEASE; BREAST CANCER; BREAST FEEDING; CROHN DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MILK LEVEL; DRUG PENETRATION; DRUG SAFETY; EMBRYOTOXICITY; ENTERITIS; FETOTOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; LACTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS VULGARIS; NONHUMAN; OLIGOSPERMIA; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PUERPERIUM; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SPERMATOZOON MOTILITY; TERATOGENICITY;

ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; BREAST FEEDING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LACTATION; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RHEUMATIC DISEASES;

EID: 77952234431     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.24     Document Type: Review

References (55)

1. Reese J, Zhao X, Ma WG, Brown N, Maziasz TJ, Dey SK: Comparative analysis of pharmacologic and/or genetic disruption of cyclooxygenase-1 and cyclooxygenase-2 function in female reproduction in mice. Endocrinology 142, 3198-3206 (2001).
2. Mendonca LLF, Khamashta MA, Nelson-Piercy C, Hughes GRV: Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology 39, 880-882 (2000).
3. Uhler ML, Hsu JW, Fisher SG, Zinaman MJ: The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil. Steril. 76, 957-961 (2001).
4. Li DK, Liu L, Odouli R: Exposure of non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ 327, 368-373 (2001
5. Ostensen M, Khamashta M, Lockshin M: Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 8 209-218 (2006). •• Comprehensive review of the data regarding medication use during pregnancy.
6. American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk. Pediatrics 108, 776-789 (2001). •• American Academy of Pediatrics compilation of agents transferred into human milk and their possible effects on the infant if known.
7. Ostensen M, Motta M: Therapy insight: the use of antirheumatic drugs during nursing. Nat. Clin. Pract. Rheumatol. 3, 400-406 (2007).
8. Benediktsson R, Calder AA, Edwards CRW, Seckl JR: Placental 11β-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin. Endocrinol. 46, 161-166 (1997).
9. Lee BH, Stoll BJ, McDonald SA, Higgins RD: Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus β-methsone. Pediatrics 121 (2), 289-296 (2008)
10. Lee BH, Stoll BJ, McDonald SA, Higgins RD: Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal β-methasone. Pediatrics 117 (5), 1503-1510 (2006)
11. Greenberger PA: Pharmacokinetics of prednisolone transfer to breast milk. Clin. Pharmacol. Ther. 53, 324-328 (1993).
12. Ost L, Wettrell G, Bjorkhem I, Rane A: Prednisolone excretion in human milk. J. Pediatr. 106 (6), 1008-1011 (1985)
13. Klinger G, Morad Y, Westall CA: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatoid disease. Lancet 358, 813-814 (2001).
14. Sperber K, Hom C, Chao CP, Shapiro D, Ash J: Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Ped. Rheumatol. 7, 9-18 (2009).
15. Parke AL, West B: Hydrocychloroquine in pregnant patients with systemic lupus erythematosus. J. Rheumatol. 23, 1715-1718 (1996).
16. Costedoat-Chalumeau N, Amoura Z, Duhaut P et al.: Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 48, 3207-3211 (2003).
17. Clowse MEB, Madger L, Witter F, Petri M: Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 54, 3640-3647 (2006).
18. Levy RA, Vilela VS, Cataldo MJ et al.: Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebocontrolled study. Lupus 10, 401-404 (2001). •• Excellent example of a randomized controlled trial of hydroxychloroquine use during pregnancy in women with lupus.
19. Costedoat-Chalumeau N, Amoura Z, Aymard G et al.: Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum. 46, 1123-1124 (2002).
20. Ostensen M, Hartmann H, Salvesen K: Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J. Rheumatol. 27, 1872-1875 (2000).
21. Chakravarty EF, Sanchez-Yamamoto D, Bush TM: The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcome. J. Rheumatol. 30, 241-246 (2003). • Population-based study of adverse pregnancy outcomes associated with rheumatoid arthritis and systemic lupus erythematosus that provides estimates of the annual incidence of women with each disease who give birth.
22. Martínez Lopez JA, Loza E, Carmona L: Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin. Exp. Rheumatol. 27, 678-684 (2009).
23. Dalrymple JM, Stamp LK, O'Donnell JL et al.: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 58, 3299-3308 (2008).
24. West SG: Methotrexate hepatotoxicity. Rheum. Dis. Clin. North Am. 23 (4), 883-915 (1997).
25. Brent RL: Teratogen update: reproductive risks of leflunomide taking leflunomide. Teratology 63, 106-112 (2001).
26. Brent RL: Teratogen update: reproductive risks of leflunomide (Arave) ; a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 63, 106-112 (2001)
27. Chambers CD, Johnson DL, Robinson LK et al.: Birth outcomes in pregnant women taking leflunomide. Arthritis Rheum. (2010) (In press). •• Excellent review of pregnancy outcomes after exposure to leflunomide by the Organization of Teratology Information Services. All infants were carefully examined by a trained dysmorphologist in a standardized fashion.
28. O'Morain C, Smethurst P, Dore CJ, Levi AJ: Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 25, 1078-1084 (1984).
29. Rahimi R, Nikfar S, Rezaie A, Abdollahi M: Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod. Toxicol. 25, 271-275 (2008).
30. Norgard B, Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT: Population based case control study of the safety of sulfasalazine used during pregnancy. Aliment. Pharmacol. Ther. 15, 483-486 (2001).
31. Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW: Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 80, 72-76 (1981).
32. Hernandez-Diaz S, Werler MM, Walker AM, Mitchel AA: Folic acid antagonists during pregnancy and the risk of birth defects. N. Engl. J. Med. 343, 1608-1614 (2000).
33. Jarnerot G, Anderson S, Esbjorner E, Sandstrom B: Albumin reserve for binding of biliruin in maternal and cord serum under treatment of sulfasalazine. Scand. J. Gastroenterol. 16, 1049-1055 (1981).
34. Esbjorner E, Jarnerot G, Wranne L: Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulfasalazine during pregnancy and lactation. Acta Paediatr. Scand. 76, 137-142 (1987).
35. Katz JA, Antoni C, Keenan GF et al.: Outcome of pregnancy in women receiving infliximab for the treatment of Crohns disease and rheumatoid arthritis. Am. J. Gastroenterol. 99, 2385-2392 (2004).
36. Mahadevan U, Kane S, Sandborn J et al.: Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohns disease. Aliment Pharmacol. Ther. 21, 733-738 (2005).
37. Goroir BP: The biosynthesis of tumor necrosis factor during pregnancy: studies with a CAT reporter transgene and TNF inhibitors. Eur. Cytokine Netw. 3, 533-537 (1992).
38. Hyrich KL, Symmons DP, Watson KD, Silman AJ: Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 54, 2701-2702 (2006). •• Excellent example of the use of a population-based registry in order to understand pregnancy outcomes.
39. Chambers CD, Johnson DL, Jones KL; OTIS Collaborative Research Group: Pregnancy outcome in women exposed to anti-TNFα medications; the OTIS Rheumatoid Arthritis in Pregnancy Study (abstract). Arthritis Rheum. 50 (Suppl.), S479 (2004).
40. Orozco C, Dao K, Cush JJ, Kavanaugh A: Safety of TNF inhibitors during pregnancy in patients with inflammatory arthritis (abstract). Arthritis Rheum. 52 (Suppl.), S344 (2005).
41. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB: A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J. Rheumatol. 36, 635-641 (2009).
42. Ali YM, Kuriya B, Orozco C, Cush JJ, Keystone EC: Can tumor necrosis factor inhibitors be safely used in pregnancy? J. Rheumatol. 37, 9-17 (2010). •• Updated review of all of the available data regarding use of TNF inhibitors during pregnancy. Provides a balanced discussion of both the risks and benefits of this therapy.
43. Ostensen M, Eigenmann GO: Etancercept in breast milk. J. Rheumatol. 31, 1017-1018 (2004).
44. Kane S, Ford J, Cohen R, Wagner C: Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J. Clin. Gastroenterol. 43 (7), 613-616 (2009).
45. Saarikoski S, Seppala M: Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am. J. Obstet. Gynecol. 115, 1100 (1973).
46. Gisbert JP: Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breastfeeding. Inflamm. Bowel Dis. DOI: 10.1002/ibd.21154 (2009) (Epub ahead of print).
47. Cleary BJ, Kallen B: Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res. A Clin. Mol. Teratol. 85, 647-654 (2009).
48. Christensen LA, Dahlerup JF, Nielsen MJ, Fallingborg JF, Schmiegelow K: Azathioprine treatment during lactation. Aliment. Pharmacol. Ther. 28, 1209-1213 (2008).
49. Merlob P, Stahl B, Klinger G: Tetrada of the possible mycophenolate mofetil embryopathy: a review. Reprod. Toxicol. 28, 105-108 (2009).
50. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Mortiz MJ, Armenti VT: Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82, 1698-1702 (2006).
51. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA: Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am. J. Med. Genet. A 149A, 1241-1248 (2009).
52. Ang GS, Simpson SA, Reddy AR: Mycophenolate mofetil embryopathy may be dose and timing dependent. Am. J. Med. Genet. A 146A, 1963-1966 (2008).
53. Enns GM, Roeder E, Chan RT, Catts ZAK, Cox VA, Golabi M: Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am. J. Med. Genet. 86, 237-241 (1999).
54. Morris PG, King F, Kennedy MJ: Cytotoxic chemotherapy for pregnancyassociated breast cancer: single institution case series. J. Oncol. Pharm. Pract. 15, 1-7 (2009).
55. Clowse MEB, Magder L, Petri M: Cyclophosphamide for lupus during pregnancy. Lupus 14, 593-597 (2006).